13 Gennaio 2023

Business Wire – 12/01/2023

IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
Do you like it?
Read more
26 Luglio 2022

Business Wire – 27/07/22

IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
Do you like it?
Read more
29 Giugno 2022

Business Wire – 29/06/22

IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
Do you like it?
Read more
24 Maggio 2022

Business Wire – 24/05/22

IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry
Do you like it?
Read more
31 Marzo 2022

Business Wire – 31/03/22

IAMA Therapeutics Announces Formation of Scientific Advisory Board
Do you like it?
Read more
11 Febbraio 2022

Business Wire – 29/03/22

IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
Do you like it?
Read more
iama-3
IAMA Therapeutics S.r.l.
iamatherapeutics@legalmail.it
Vat: 02775040997
Address
Via Filippo Turati, 2
16128 Genoa Italy
Contact
info@iamatherapeutics.com

Cookie Policy - Privacy Policy
Powered by Hetaweb - www.hetaweb.it